Skip to product information
Binimetinib-LuciBinim
KSh43,200.00
|
What it treats: |
Binimetinib is an oral MEK inhibitor used mainly in cancers driven by MAPK pathway mutations. |
|
Melanoma |
Unresectable or Metastatic Melanoma with BRAF V600E or V600K Mutation Used in combination with encorafenib (a BRAF inhibitor) in adults. This combination helps block the MAPK/ERK pathway at two points (BRAF and MEK), improving efficacy and delaying resistance. NRAS-Mutant Melanoma (some regions, not FDA-approved in US) As a single agent in patients with unresectable or metastatic melanoma with NRAS mutations (approved in the EU). |